Cargando…

Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis

BACKGROUND: Autoantibodies, in particular those against aquaporin-4 and myelin-oligodendrocyte glycoprotein (MOG), aid as biomarkers in the differential diagnosis of demyelination. Here, we report on discovery of autoantibodies against flotillin in patients with multiple sclerosis (MS). METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, S., Trendelenburg, G., Scharf, M., Denno, Y., Brakopp, S., Teegen, B., Probst, C., Wandinger, K. P., Buttmann, M., Haarmann, A., Szabados, F., vom Dahl, M., Kümpfel, T., Eichhorn, P., Gold, H., Paul, F., Jarius, S., Melzer, N., Stöcker, W., Komorowski, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481867/
https://www.ncbi.nlm.nih.gov/pubmed/28645295
http://dx.doi.org/10.1186/s12974-017-0900-z
_version_ 1783245471304646656
author Hahn, S.
Trendelenburg, G.
Scharf, M.
Denno, Y.
Brakopp, S.
Teegen, B.
Probst, C.
Wandinger, K. P.
Buttmann, M.
Haarmann, A.
Szabados, F.
vom Dahl, M.
Kümpfel, T.
Eichhorn, P.
Gold, H.
Paul, F.
Jarius, S.
Melzer, N.
Stöcker, W.
Komorowski, L.
author_facet Hahn, S.
Trendelenburg, G.
Scharf, M.
Denno, Y.
Brakopp, S.
Teegen, B.
Probst, C.
Wandinger, K. P.
Buttmann, M.
Haarmann, A.
Szabados, F.
vom Dahl, M.
Kümpfel, T.
Eichhorn, P.
Gold, H.
Paul, F.
Jarius, S.
Melzer, N.
Stöcker, W.
Komorowski, L.
author_sort Hahn, S.
collection PubMed
description BACKGROUND: Autoantibodies, in particular those against aquaporin-4 and myelin-oligodendrocyte glycoprotein (MOG), aid as biomarkers in the differential diagnosis of demyelination. Here, we report on discovery of autoantibodies against flotillin in patients with multiple sclerosis (MS). METHODS: The target antigen was identified by histo-immunoprecipitation using the patients’ sera and cryosections of rat or pig cerebellum combined with mass spectrometrical analysis. Correct identification was ascertained by indirect immunofluorescence and neutralization tests using the target antigens recombinantly expressed in HEK293 cells. RESULTS: Serum and CSF of the index patient produced a fine-granular IgG indirect immunofluorescence staining of the hippocampal and cerebellar molecular layers. Flotillin-1 and flotillin-2 were identified as target autoantigens. They also reacted with recombinant human flotillin-1/2 co-expressed in HEK293 cells, but not with the individual flotillins in fixed- and live-cell assays. Moreover, neutralization using flotillin-1/2, but not the single flotillins, abolished the tissue reactivity of patient serum. Screening of 521 patients, for whom anti-aquaporin-4 testing was requested and negative, revealed 8 additional patients with anti-flotillin-1/2 autoantibodies. All eight were negative for anti-MOG. Six patients ex post fulfilled the revised McDonald criteria for MS. Vice versa, screening of 538 MS sera revealed anti-flotillin-1/2 autoantibodies in eight patients. The autoantibodies were not found in a cohort of 67 patients with other neural autoantibody-associated syndromes and in 444 healthy blood donors. CONCLUSIONS: Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved in axon outgrowth and regeneration of the optic nerve, are present in 1–2% of patients with bona fide MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-017-0900-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5481867
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54818672017-06-23 Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis Hahn, S. Trendelenburg, G. Scharf, M. Denno, Y. Brakopp, S. Teegen, B. Probst, C. Wandinger, K. P. Buttmann, M. Haarmann, A. Szabados, F. vom Dahl, M. Kümpfel, T. Eichhorn, P. Gold, H. Paul, F. Jarius, S. Melzer, N. Stöcker, W. Komorowski, L. J Neuroinflammation Research BACKGROUND: Autoantibodies, in particular those against aquaporin-4 and myelin-oligodendrocyte glycoprotein (MOG), aid as biomarkers in the differential diagnosis of demyelination. Here, we report on discovery of autoantibodies against flotillin in patients with multiple sclerosis (MS). METHODS: The target antigen was identified by histo-immunoprecipitation using the patients’ sera and cryosections of rat or pig cerebellum combined with mass spectrometrical analysis. Correct identification was ascertained by indirect immunofluorescence and neutralization tests using the target antigens recombinantly expressed in HEK293 cells. RESULTS: Serum and CSF of the index patient produced a fine-granular IgG indirect immunofluorescence staining of the hippocampal and cerebellar molecular layers. Flotillin-1 and flotillin-2 were identified as target autoantigens. They also reacted with recombinant human flotillin-1/2 co-expressed in HEK293 cells, but not with the individual flotillins in fixed- and live-cell assays. Moreover, neutralization using flotillin-1/2, but not the single flotillins, abolished the tissue reactivity of patient serum. Screening of 521 patients, for whom anti-aquaporin-4 testing was requested and negative, revealed 8 additional patients with anti-flotillin-1/2 autoantibodies. All eight were negative for anti-MOG. Six patients ex post fulfilled the revised McDonald criteria for MS. Vice versa, screening of 538 MS sera revealed anti-flotillin-1/2 autoantibodies in eight patients. The autoantibodies were not found in a cohort of 67 patients with other neural autoantibody-associated syndromes and in 444 healthy blood donors. CONCLUSIONS: Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved in axon outgrowth and regeneration of the optic nerve, are present in 1–2% of patients with bona fide MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-017-0900-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-23 /pmc/articles/PMC5481867/ /pubmed/28645295 http://dx.doi.org/10.1186/s12974-017-0900-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hahn, S.
Trendelenburg, G.
Scharf, M.
Denno, Y.
Brakopp, S.
Teegen, B.
Probst, C.
Wandinger, K. P.
Buttmann, M.
Haarmann, A.
Szabados, F.
vom Dahl, M.
Kümpfel, T.
Eichhorn, P.
Gold, H.
Paul, F.
Jarius, S.
Melzer, N.
Stöcker, W.
Komorowski, L.
Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title_full Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title_fullStr Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title_full_unstemmed Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title_short Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
title_sort identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481867/
https://www.ncbi.nlm.nih.gov/pubmed/28645295
http://dx.doi.org/10.1186/s12974-017-0900-z
work_keys_str_mv AT hahns identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT trendelenburgg identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT scharfm identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT dennoy identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT brakopps identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT teegenb identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT probstc identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT wandingerkp identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT buttmannm identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT haarmanna identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT szabadosf identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT vomdahlm identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT kumpfelt identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT eichhornp identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT goldh identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT paulf identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT jariuss identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT melzern identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT stockerw identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis
AT komorowskil identificationoftheflotillin12heterocomplexasatargetofautoantibodiesinbonafidemultiplesclerosis